<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243837</url>
  </required_header>
  <id_info>
    <org_study_id>LYT-100-2020-01</org_study_id>
    <nct_id>NCT04243837</nct_id>
  </id_info>
  <brief_title>LYT-100 in Healthy Volunteers and BCRL</brief_title>
  <official_title>A Phase 1/1b MAD and Food Effect Study in Healthy Volunteers of Deupirfenidone (LYT-100) Followed by Further Exploration in Patients With BRCL Upper Limb Secondary Lymphoedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PureTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PureTech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine
      safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.

      Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fasted
      conditions.

      Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and
      exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: This is a randomised, double-blind, placebo-controlled, multiple ascending dose
      design to assess the safety, tolerability and PK profile of multiple doses of LYT-100
      administered under fed conditions at steady state in healthy participants. Up to 4 dosing
      cohorts are planned.

      Part 2: The dose level immediately below the maximally tolerated dose in Part 1 will be used
      in Part 2. Following a minimum 7-day washout of the cohort that received this dose, subjects
      in Part 2 will be administered a single dose of their assigned treatment under fasting
      conditions to permit a comparison of the rate and extent of absorption of LYT-100 under
      fasting conditions to the equivalent dose in a prior fed cohort.

      Part 3: Once the optimal dose and regimen is determined with or without food, Part 3 will
      follow with an open-label, single treatment arm to assess the safety, tolerability, PK,
      biomarkers and effect on exploratory clinical endpoints of LYT-100 over a period of up to
      6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel
      lymph node biopsy and/or axillary node dissection, with or without radiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 consists of 4 cohorts with active treatment or placebo Part 2 consists of 1 cohort with active treatment or placebo Part 3 consists of 1 cohort with active treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Part 1 and Part 2 are double-blind during the data collection. Determination for dose escalation maybe made under unblinded conditions by assessors.
Part 3 is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Evaluate the safety and tolerability of LYT-100 as measured by TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use pharmacokinetics to characterize the plasma concentration of LYT-100</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Measure observed concentration of LYT-100 in blood plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetic profile of LYT-100 based on plasma concentration of LYT-100</measure>
    <time_frame>2 days (main time frame)</time_frame>
    <description>Measure concentration of LYT-100 in blood plasma in fed or fasted subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Breast Cancer Related Lymphoedema</condition>
  <condition>Lymphoedema</condition>
  <arm_group>
    <arm_group_label>LYT-100 in healthy volunteers with Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100, multiple ascending</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in healthy volunteers with Food</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, multiple administrations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-100 in healthy volunteers, Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100, Dose below MTD for 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in healthy volunteers, Fasted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, for 1 administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-100 in patients with BCRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100 for 6 months, dose and regimen to be determined</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100</intervention_name>
    <description>LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.
Cohorts 1 to 4 (HV subjects) will receive multiple ascending doses, starting at 100 mg BID up to 750 mg, with food for 5-days.</description>
    <arm_group_label>LYT-100 in healthy volunteers with Food</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Inactive capsule(s)</description>
    <arm_group_label>Placebo in healthy volunteers with Food</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100</intervention_name>
    <description>LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.
Cohort 5 (HV subjects) will receive a dose level below MTD, fasting for 1-day.</description>
    <arm_group_label>LYT-100 in healthy volunteers, Fasted</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Inactive capsule(s)</description>
    <arm_group_label>Placebo in healthy volunteers, Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100</intervention_name>
    <description>LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.
Cohort 6 (patients with BCRL) will receive an optimally tolerated dose BID, with or without food, for up to 6-months.</description>
    <arm_group_label>LYT-100 in patients with BCRL</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

        Part 1 and 2: Healthy Volunteers

          1. Male or female between 18 and 75 years old (inclusive) at the time of screening.

          2. In good general health at screening, free from clinically significant unstable
             medical, surgical or psychiatric illness, at the discretion of the Investigator.

        Part 3: Patients with BRCL

          1. Female or male between 18 and 80 years old (inclusive) at the time of informed
             consent.

          2. At least 6 months since any type of breast cancer surgery (excluding fine needle
             aspiration biopsy [FNA]), at the time of study screening. No intention to have breast
             reconstructive surgery, nipple reconstruction and/or tattooing during the course of
             the study.

          3. At least 3 months since completion of all types of treatment for breast cancer,
             including but not limited to neoadjuvant, radiotherapy, chemotherapy and
             immunotherapy, at the time of study screening.

          4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2
             therapy at the time of screening, with no planned changes to this therapy throughout
             the duration of the study.

          5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast
             cancer and/or metastasis for at least 6 months since breast cancer surgery, as
             determined at screening and baseline.

          6. Documented evidence of Stage 1 or 2 lymphoedema.

          7. Receiving standard of care compression or agreeable to using care compression, or no
             compression at all â‰¥ 4 weeks prior to screening and throughout the study.

        Main Exclusion Criteria:

        Part 1 and 2: Healthy Volunteers

          1. History or presence of malignancy at screening or baseline, with the exception of
             adequately treated localised skin cancer (basal cell or squamous cell carcinoma) or
             carcinoma in-situ of the cervix.

          2. Clinically significant infection within 28 days of the start of dosing, or infections
             requiring parenteral antibiotics within the 6 months prior to screening.

          3. Chronic administration (defined as more than 14 consecutive days) of
             immunosuppressants or other immune-modifying drugs within 3 months prior to study drug
             administration; corticosteroids are permitted at the discretion of the Investigator).

          4. History or presence at screening or baseline of a condition associated with
             significant immunosuppression

        Part 3: Patients with BRCL

          1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e.,
             sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or
             lymphatic or vascular malformation, determined at screening.

          2. Chronic administration (defined as more than 14 consecutive days) of
             immunosuppressants or other immune-modifying drugs within 3 months prior to study drug
             administration; corticosteroids are permitted at the discretion of the PI.

          3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis,
             dermatitis, necrotising fasciitis, or current open wounds or sores in the affected
             extremity.

          4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema
             greater than 2 years, determined at screening.

          5. Initiated use of compression or manual lymphatic drainage or other lymphoedema
             therapies at the start of the study within 4 weeks of the screening visit. Rescreening
             is allowed following a course of stable compression regimen of &gt; 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LuAnn Sabounjian</last_name>
    <phone>774-292-9118</phone>
    <email>ls@puretechhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Chen</last_name>
    <phone>617-553-9870</phone>
    <email>mc@puretechhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nucleus Network VIC</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lickliter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

